Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omeros Corp.

www.omeros.com

Latest From Omeros Corp.

Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.

Drug Review Approvals

Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

Business Strategies Commercial

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific

Placebo Effect or Just Bad News? Omeros Down On OMS721 IgA Nephropathy Data

Investors and analysts hope Omeros Corp can explain – and soon - why its candidate drug for treating renal diseases performed only slightly better than placebo in tests on IgA nephropathy patients with high risk of progression, sending the biotech's shares sliding.

Clinical Trials Renal
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • Generic Drugs
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Inflammation
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Omeros Corp.
  • Senior Management
  • Gregory A Demopulos, MD, Chmn. & CEO
    Timothy M Duffy, PhD, VP, Bus. Dev.
    George A Gaitanaris, MD, PhD, CSO
    Eckard Leifke, MD, VP, Clin. Dev. & CMO
  • Contact Info
  • Omeros Corp.
    Phone: (206) 676-5000
    201 Elliott Ave. W.
    Seattle, WA 98119
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register